PGDM1400

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Boris Juelg, MD PhD

Conditions

Acquired Immunodeficiency SyndromeHIVHIV InfectionsImmunologic Deficiency Syndrome, AcquiredRetroviridae InfectionsSexually Transmitted Diseases, Viral

Phase 1

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

CompletedNCT03928821

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-07-17End: 2021-03-25Updated: 2022-07-11

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Active, not recruitingNCT04983030

Boris Juelg, MD PhDAcquired Immunodeficiency Syndrome, HIV, Immunologic Deficiency Syndrome, Acquired +2

Start: 2022-04-01End: 2026-04-30Target: 36Updated: 2026-01-12

Related Papers

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.

2023-10-0126 citations

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.

2022-05-12112 citations